MDGL
Price
$293.64
Change
+$20.85 (+7.64%)
Updated
Jan 17 closing price
Capitalization
6.4B
39 days until earnings call
TBPH
Price
$8.58
Change
+$0.14 (+1.66%)
Updated
Jan 17 closing price
Capitalization
421.92M
44 days until earnings call
Ad is loading...

MDGL vs TBPH

Header iconMDGL vs TBPH Comparison
Open Charts MDGL vs TBPHBanner chart's image
Madrigal Pharmaceuticals
Price$293.64
Change+$20.85 (+7.64%)
Volume$866.12K
Capitalization6.4B
Theravance Biopharma
Price$8.58
Change+$0.14 (+1.66%)
Volume$166.56K
Capitalization421.92M
MDGL vs TBPH Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TBPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. TBPH commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and TBPH is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (MDGL: $293.64 vs. TBPH: $8.58)
Brand notoriety: MDGL and TBPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 220% vs. TBPH: 83%
Market capitalization -- MDGL: $6.4B vs. TBPH: $421.92M
MDGL [@Biotechnology] is valued at $6.4B. TBPH’s [@Biotechnology] market capitalization is $421.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileTBPH’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • TBPH’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than TBPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 3 TA indicator(s) are bullish while TBPH’s TA Score has 3 bullish TA indicator(s).

  • MDGL’s TA Score: 3 bullish, 5 bearish.
  • TBPH’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, TBPH is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а -13.36% price change this week, while TBPH (@Biotechnology) price change was -2.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

MDGL is expected to report earnings on May 13, 2025.

TBPH is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.4B) has a higher market cap than TBPH($422M). MDGL YTD gains are higher at: -4.838 vs. TBPH (-8.820). TBPH has higher annual earnings (EBITDA): -33.83M vs. MDGL (-502.65M). MDGL has more cash in the bank: 999M vs. TBPH (91.4M). TBPH has less debt than MDGL: TBPH (45M) vs MDGL (119M). MDGL has higher revenues than TBPH: MDGL (76.8M) vs TBPH (63.2M).
MDGLTBPHMDGL / TBPH
Capitalization6.4B422M1,518%
EBITDA-502.65M-33.83M1,486%
Gain YTD-4.838-8.82055%
P/E RatioN/AN/A-
Revenue76.8M63.2M122%
Total Cash999M91.4M1,093%
Total Debt119M45M264%
FUNDAMENTALS RATINGS
MDGL vs TBPH: Fundamental Ratings
MDGL
TBPH
OUTLOOK RATING
1..100
1956
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
30100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
5079
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TBPH's Valuation (36) in the Pharmaceuticals Other industry is in the same range as MDGL (68). This means that TBPH’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (30) in the Pharmaceuticals Other industry is significantly better than the same rating for TBPH (100). This means that MDGL’s stock grew significantly faster than TBPH’s over the last 12 months.

TBPH's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as MDGL (99). This means that TBPH’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Price Growth Rating (50) in the Pharmaceuticals Other industry is in the same range as TBPH (79). This means that MDGL’s stock grew similarly to TBPH’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as TBPH (100). This means that MDGL’s stock grew similarly to TBPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLTBPH
RSI
ODDS (%)
Bearish Trend 11 days ago
73%
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
76%
Momentum
ODDS (%)
Bullish Trend 11 days ago
76%
Bearish Trend 11 days ago
71%
MACD
ODDS (%)
Bullish Trend 11 days ago
81%
N/A
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
76%
Bearish Trend 11 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
76%
Bearish Trend 11 days ago
73%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 24 days ago
73%
Declines
ODDS (%)
Bearish Trend 19 days ago
81%
Bearish Trend 17 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
71%
Bullish Trend 11 days ago
73%
Aroon
ODDS (%)
Bearish Trend 11 days ago
79%
Bearish Trend 11 days ago
76%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TBPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSGCX24.820.28
+1.14%
JHancock U.S. Growth C
HSWTX17.980.09
+0.50%
Hartford Schroders International Stk R5
GWILX15.990.07
+0.44%
Glenmede Women in Leadership US Eq
NVSCX32.540.05
+0.15%
Allspring Small Company Growth Admin
MDFSX7.82N/A
N/A
Manning & Napier Disciplined Value S

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+7.64%
KANT - MDGL
62%
Loosely correlated
N/A
VXRT - MDGL
61%
Loosely correlated
-0.20%
ALXO - MDGL
56%
Loosely correlated
+6.75%
REPL - MDGL
55%
Loosely correlated
-2.12%
ZNTL - MDGL
51%
Loosely correlated
-6.28%
More

TBPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with ELEV. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then ELEV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TBPH
1D Price
Change %
TBPH100%
+1.66%
ELEV - TBPH
46%
Loosely correlated
+6.24%
AXON - TBPH
34%
Loosely correlated
+1.37%
ARRY - TBPH
34%
Loosely correlated
-0.14%
CDXS - TBPH
32%
Poorly correlated
+1.63%
MDGL - TBPH
30%
Poorly correlated
+7.64%
More